Other substances

VH2 A01-B02

A bi-paratopic anti-SARS-CoV-2 spike protein antibody/nanobody construct.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

VH2 A01-B02 is a bi-paratopic construct containing two (A01 and B02) VH domains derived from Trastuzumab. The VHs have been modified and selected using masked phage selection for their affinity to the SARS-CoV-2 spike protein (Bracken et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
Spike protein In vitro Antibody 		HEK-ACE2 cells; Vero E6 cells; SARS-CoV-2 virus clinical isolate 2019-nCoV/USA-WA1/2020 12.15

The bi-paratopic construct can potently neutralize pseudotyped-SARS-CoV-2 (IC50 1.08 nM) and block authentic SARS-CoV-2 viral entry (IC50 26.2 nM) in vitro.

 Oct/20/2020
Export (.csv)